Skip to main content
Quest Diagnostics

Evaluating Patient-Reported Outcomes and Wearable Data among Individuals with Relapsed/Refractory Multiple Myeloma

ASH 2023

American Society of Hematology

San Diego, CA Dec 9-12, 2023

Poster presentation: Evaluating Patient-Reported Outcomes and Wearable Data among Individuals with Relapsed/Refractory Multiple Myeloma

Authors: Banerjee R, Brassil K, Grossfeld T, Austin Barr A,Cowan AJ

Specialty: Oncology, Hematology

Disclaimer: One or more of the authors of this abstract were employed at the time by Pack Health, a subsidiary of Quest Diagnostics.

Related content

Conference Presentation
Updated trial in progress: understanding treatment experience of individuals receiving isatuximab using both patient-reported outcomes and wearable data
Publication
Randomized Phase 2 Study of Digital Life Coaching During Transplantation for Myeloma
On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care
On-Demand Webinar
Innovations within Precision Oncology Evolution of a Biomarker a Case Study of KRAS-G12C
Audio Podcast
Optimize Oncology Care with Clinical Pathways

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.